Federated Hermes
MLNT

Federated Hermes’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Federated Hermes’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-110
Closed -$4K – 2308
2018
Q1 		$4K Sell
110
-378
-77% -$24.9K ﹤0.01% 2012
2017
Q4 		$39K Buy
+488
New +$36.1K ﹤0.01% 1692

Other funds holding MLNT

OH
Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Federated Hermes's MLNT Position: Q2 2018 in Review

Federated Hermes sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q2 2018, closing a stake of 110 shares — an estimated $4K sold.

Federated Hermes first reported a position in MLNT in Q4 2017 and held it in 2 quarters. The position peaked at $39K in Q4 2017. 87 funds tracked by Wall St. Rank hold MLNT as of Q2 2018.

  • Federated Hermes reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Federated Hermes sold 110 Melinta Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $4K.
  • Federated Hermes first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Federated Hermes's Melinta Therapeutics, Inc. Common Stock position peaked at $39K in Q4 2017.
  • 87 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Federated Hermes's 13F filing for Q2 2018, filed 10 Aug 2018.